Skip to main content
Suzanne Lentzsch, MD, Hematology, New York, NY

SuzanneLentzschMD

Hematology New York, NY

Hematologic Oncology

Professor of Medicine at CUMC, Director, Multiple Myeloma and Amyloidosis Program

Overview of Dr. Lentzsch

Dr. Suzanne Lentzsch is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NewYork-Presbyterian/Lawrence Hospital. She received her medical degree from Humboldt University of Berlin- Charite Faculty of Medicine and has been in practice 27 years. Dr. Lentzsch accepts several types of health insurance, listed below. She is one of 64 doctors at New York-Presbyterian Hospital and one of 25 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Hematology. She has more than 100 publications and over 500 citings.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2001
  • Humboldt University School of Medicine
    Humboldt University School of MedicinePh.D, Cum Laude, 1990 - 1994
  • Humboldt University of Berlin - Charite Faculty of Medicine
    Humboldt University of Berlin - Charite Faculty of MedicineClass of 1990

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2011 - 2025
  • PA State Medical License
    PA State Medical License 2006 - 2024

Awards, Honors, & Recognition

  • Woman of the year Candidate Leukemia Lymphoma Society, 2014
  • Laugh for Life Honorary Chair MMRF, 2014
  • Leukemia Diploma For a selection of worthy articles in 2012/2013 Leukemia, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Disrupted Radial and Tibial Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined Significance  
    E Shane, E M Stein, S Lentzsch, J Fu, Osteoporosis international
  • Selinexor plus Low-Dose Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma  
    Suzanne Lentzsch, Cristina Gasparetto, Blood
  • Beyond NEOD001 for Systemic Light-Chain Amyloidosis  
    Suzanne Lentzsch, Cindy Varga, Blood
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
    Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
    Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance
    Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Untangling Amyloidosis 2018 
    60th American Society of Hematology Annual Meeting - 11/30/2018
  • Bone Disease in Multiple Myeloma 
    ENDO 2018: 100th Endocrine Society Annual Meeting - Chicago, Illinios - 03/17/2018
  • What is Optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients completing induction 
    New York, NY - 1/1/2015
  • Join now to see all

Other

Press Mentions

  • Curative Approach to Smoldering Myeloma May Prevent Progression
    Curative Approach to Smoldering Myeloma May Prevent ProgressionAugust 7th, 2024
  • Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL
    Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLLDecember 5th, 2022
  • Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemia
    Ibrutinib-Rituximab Wins Out in Waldenstrom's MacroglobulinemiaOctober 11th, 2021
  • Join now to see all

Insurance Accepted

  • CIGNA HMO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Healthfirst New York
    HIP of New York - Select PPO
    MagnaCare PPO
    Multiplan PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
  • Please verify your coverage with the provider's office directly when scheduling an appointment